SCHEMBL1856249

SCHEMBL1856249

Cc1ccc(-c2cc(N)[nH]n2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 2/20 0.45
WDR77 Q9BQA1 2/20 0.45
HPGDS O60760 1/20 0.45
ALK Q9UM73 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
PTGS2 P35354 3/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALPL P05186 4/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TDO2 P48775 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13162521 0.82 ALK (0.62) PRMT5WDR77HPGDSALKPTGS2
SCHEMBL12692668 0.79 PIK3CD (0.50) HPGDSPIK3CDRAB9ANPC1ALPL
SCHEMBL210885 0.79 MKNK1 (0.48) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL1143959 0.78 ALPL (0.54) RAB9ANPC1SMN1; SMN2ALPLCYP1A2
SCHEMBL2845103 0.78 PLA2G10 (0.52) RAB9ANPC1SMN1; SMN2ALPLALDH1A1
SCHEMBL30129593 0.76 MAP4K4 (0.46) PIK3CB
SCHEMBL22191645 0.76 MAP4K4 (0.46) PIK3CB
SCHEMBL19367483 0.76 PRMT5 (0.41) PRMT5WDR77HPGDSALKRAB9A
SCHEMBL21774002 0.76 KCNH2 (0.46) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL22333570 0.76 TRPA1 (0.42) PIK3CDPIK3CAPIK3CBPI4KBALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323988-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS Wyeth LLC (US) 2011-05-25 EP disclosed
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-05-27 US disclosed
WO-2010009290-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-01-21 WO disclosed
WO-2010009290-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS CHRNA7, CHRNA6, CHRNA2 PRMT5 1122/4885WDR77 1481/4885HPGDS 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.